证券研究报告 精细运营与供应链提效有望驱动业绩 持续释放 华泰研究 动态点评 投资评级(维持): 买入 万辰集团 (300972 CH) 目标价(人民币): 276.00 樊俊豪 研究员 SAC No. S0570524050001 SFC No. BDO986 SAC No. S0570524090003 SFC No. BVO045 曾珺 研究员 SAC No. S0570523120004 SFC No. BTM417 季珂* 研究员 SAC No. S0570525080003 jike@htsc.com +(86) 21 2897 2228 石狄 研究员 shidi@htsc.com 吕若晨 研究员 SAC No. S0570525050002 SFC No. BEE828 lvruochen@htsc.com +(86) 755 8249 2388 基本数据 | 收盘价 (人民币 截至 1 月 27 日) | 228.12 | | --- | --- | | 市值 (人民币百万) | 43,090 | | 6 个月平均日成交额 (人民币百万) | 458.98 | | 52 周价格范围 (人民币) ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company's Q4 performance met expectations, with a total revenue of 20.03 billion yuan for 2025, representing a year-on-year increase of 48%. The net profit attributable to shareholders was 754.9 million yuan, up 52.79% year-on-year [7] - The company has seen steady growth in lithium cobalt oxide shipments, with a total sales volume of 65,300 tons in 2025, a 41% increase year-on-year. The profitability remains high, with a projected net profit of over 10,000 yuan per ton in Q4 [7] - The company is experiencing stable growth in ternary and lithium iron phosphate sales, with total sales of 77,000 tons in 2025, a 48% increase year-on-year. The company expects to achieve profitability in lithium iron phosphate sales in 2026 [7] - The solid-state battery business is progressing well, with the company having established a production capacity of 10 tons in 2025 and plans for a hundred-ton production line in 2026 [7] - The profit forecast for 2025-2027 has been adjusted downwards due to increased expense provisions, with net profits projected at 7.5 billion, 10.5 billion, and 12.7 billion yuan respectively [7] Financial Summary - Total revenue for 2023 is projected at 17.31 billion yuan, with a year-on-year decrease of 39.79%. For 2024, revenue is expected to be 13.3 billion yuan, a decrease of 23.19% [1][8] - The net profit attributable to shareholders for 2023 is estimated at 527.45 million yuan, down 52.93% year-on-year, and for 2024, it is projected at 494.07 million yuan, a decrease of 6.33% [1][8] - The earnings per share (EPS) for 2023 is expected to be 1.05 yuan, decreasing to 0.98 yuan in 2024 [1][8] - The price-to-earnings (P/E) ratio is projected to be 88.99 for 2023, decreasing to 95.00 for 2024, and further down to 62.18 for 2025 [1][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company's Q4 performance met expectations, with a total revenue of 20.03 billion yuan for 2025, representing a year-on-year increase of 48%. The net profit attributable to shareholders was 754.9 million yuan, up 52.79% year-on-year [7] - The company has seen steady growth in lithium cobalt oxide shipments, with a total sales volume of 65,300 tons in 2025, a 41% increase year-on-year. The profitability remains high, with a projected net profit of over 10,000 yuan per ton in Q4 [7] - The company is experiencing stable growth in ternary and lithium iron phosphate sales, with total sales of 77,000 tons in 2025, a 48% increase year-on-year. The company expects to achieve profitability in lithium iron phosphate sales in 2026 [7] - The solid-state battery business is progressing well, with the company having established a production capacity of 10 tons in 2025 and plans for a 100-ton production line in 2026 [7] - The profit forecast for 2025-2027 has been adjusted downwards due to increased expense provisions, with net profits projected at 7.5 billion, 10.5 billion, and 12.7 billion yuan respectively [7] Financial Summary - Total revenue for 2025 is projected at 20.03 billion yuan, with a year-on-year growth rate of 50.65% for 2026 and 10.21% for 2027 [8] - The net profit attributable to shareholders is expected to reach 754.9 million yuan in 2025, with growth rates of 52.79%, 39.70%, and 20.81% for the following years [8] - The latest diluted EPS is projected to be 1.50 yuan for 2025, increasing to 2.09 yuan in 2026 and 2.52 yuan in 2027 [8] - The P/E ratio is expected to decrease from 62.18 in 2025 to 36.84 in 2027, indicating improving valuation metrics [8]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of RMB 96.40 [1]. Core Insights - The company, Ugreen Technology, is expanding its AI+NAS ecosystem, positioning NAS as a central hub for home data while launching the SynCare smart security series [1][6]. - The company expects a net profit attributable to shareholders for 2025 to be between RMB 653 million and RMB 733 million, aligning with expectations [1][6]. - Ugreen's revenue is projected to grow significantly, driven by strong performance in NAS and mobile power products, with sales on e-commerce platforms increasing by 127% and 227% respectively [6]. Financial Projections - Revenue forecasts for the company are as follows: - 2024: RMB 6,170 million (up 28.46%) - 2025: RMB 9,236 million (up 49.70%) - 2026: RMB 12,500 million (up 35.34%) - 2027: RMB 15,611 million (up 24.89%) [5]. - Net profit attributable to shareholders is expected to be: - 2024: RMB 462.28 million (up 19.29%) - 2025: RMB 706.14 million (up 52.75%) - 2026: RMB 1,000 million (up 41.64%) - 2027: RMB 1,346 million (up 34.57%) [5]. - The company’s EPS is projected to be: - 2024: RMB 1.11 - 2025: RMB 1.70 - 2026: RMB 2.41 - 2027: RMB 3.24 [5]. Product Launches and Innovations - Ugreen announced the pre-sale of its AI NAS products, which will be available on Kickstarter in March, featuring advanced specifications and AI capabilities [7]. - The SynCare series was showcased at CES 2026, including various smart security products that integrate with NAS for enhanced home security [8]. Valuation and Market Position - The company is expected to enjoy a valuation premium, with a target PE of 40 times for 2026, leading to a target price of RMB 96.40 [9]. - The company’s market capitalization is approximately RMB 29,044 million, with a closing price of RMB 70.00 as of January 27 [2].

证券研究报告 万辰集团 (300972 CH) 精细运营与供应链提效有望驱动业绩 持续释放 华泰研究 动态点评 投资评级(维持): 买入 石狄 研究员 shidi@htsc.com SAC No. S0570524090003 SFC No. BVO045 目标价(人民币): 276.00 樊俊豪 研究员 SAC No. S0570524050001 SFC No. BDO986 曾珺 研究员 SAC No. S0570523120004 SFC No. BTM417 季珂* 研究员 SAC No. S0570525080003 jike@htsc.com +(86) 21 2897 2228 吕若晨 研究员 SAC No. S0570525050002 SFC No. BEE828 lvruochen@htsc.com +(86) 755 8249 2388 基本数据 | 收盘价 (人民币 截至 1 月 27 日) | 228.12 | | --- | --- | | 市值 (人民币百万) | 43,090 | | 6 个月平均日成交额 (人民币百万) | 458.98 | | 52 周价格范围 (人民币) ...

证券研究报告·公司点评报告·证券ⅡII 国泰海通（601211） 执业证书：S0600524120001 sunt@dwzq.com.cn 证券分析师 何婷 执业证书：S0600524120009 heting@dwzq.com.cn 2025 年业绩预增点评：扣非净利润同比增长 69-73%，低估值向上空间大 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 36,141 | 43,397 | 54,733 | 67,286 | 70,996 | | 同比（%） | 1.89% | 20.08% | 26.12% | 22.93% | 5.51% | | 归母净利润（百万元） | 9,374 | 13,024 | 27,747 | 28,169 | 30,429 | | 同比（%） | -18.54% | 38.94% | 113.04% | 1.52% | 8.02% | | EPS-最新摊薄（元/股） | 1 ...

Investment Rating - The investment rating for Guotai Haitong is "Buy" (maintained) [1] Core Views - Guotai Haitong announced a profit forecast for 2025, expecting a net profit attributable to shareholders of 27.5-28 billion yuan, representing a year-on-year growth of 111%-115%. The non-recurring net profit is expected to be 21.1-21.5 billion yuan, with a year-on-year increase of 69%-73% [2] - The profit growth in 2025 is primarily driven by brokerage, investment banking, and proprietary trading businesses [3] Financial Summary - Total revenue forecast for 2025 is 54.733 billion yuan, with a year-on-year growth of 26.12% [1] - The net profit attributable to shareholders for 2025 is projected at 27.747 billion yuan, reflecting a year-on-year increase of 113.04% [1] - The latest diluted EPS for 2025 is estimated at 1.57 yuan per share, with a P/E ratio of 12.29 [1] - The fourth quarter is expected to see a non-recurring net profit of 4.8-5.2 billion yuan, with a quarter-on-quarter decline of 42-47% due to high base effects and a 1.6 billion yuan impairment provision [2]

Investment Rating - The report assigns an investment rating of "Buy" for the company, indicating a positive outlook based on its stable generics business and growth potential in small nucleic acid drugs [5]. Core Insights - The company has a solid foundation in generics, with a stable growth phase, and is strategically positioning itself in the small nucleic acid innovation space, which is expected to drive long-term growth [7][10]. - The generics business is projected to maintain steady cash flow, while the innovative drug segment is anticipated to create a second growth curve, enhancing the company's overall valuation [8][10]. Summary by Relevant Sections Market Performance - The closing price of the company's stock is 28.82 yuan, with a market capitalization of 13,833.60 million yuan [3]. Financial Forecast and Valuation - Revenue projections for 2023 to 2027 are as follows: 3,340 million yuan (2023), 3,446 million yuan (2024), 3,472 million yuan (2025E), 3,852 million yuan (2026E), and 4,266 million yuan (2027E) [6]. - The expected growth rates for revenue are 3.07% (2023), 3.17% (2024), 0.75% (2025), 10.95% (2026), and 10.74% (2027) [6]. - The projected net profit for the same years is 489 million yuan (2023), 489 million yuan (2024), 465 million yuan (2025), 481 million yuan (2026), and 520 million yuan (2027) [6]. - The company’s price-to-earnings (P/E) ratios are estimated at 28.30 (2023), 28.31 (2024), 29.78 (2025), 28.76 (2026), and 26.61 (2027) [6]. Business Overview - The company, formerly known as Wansheng Pharmaceutical, has been in the generics business for over 20 years and has recently expanded into innovative drugs, particularly small nucleic acids [7]. - As of the first half of 2025, the company holds 209 domestic drug registration approvals, with a revenue contribution of 32.09 billion yuan from drug formulations, accounting for 93% of total revenue [7][20]. - The company’s core therapeutic areas include cardiovascular, diabetes, digestive, skin diseases, and chronic kidney disease, which collectively contribute 77% of its revenue [20]. Growth Drivers - The generics business is entering a stable growth phase, with a compound annual growth rate (CAGR) of 7.75% from 2019 to 2024 [10]. - The company is actively investing in small nucleic acid drugs, with R&D expenses increasing from 180 million yuan in 2021 to 417 million yuan in 2024 [10][49]. - The N-ER platform for nucleic acid drug delivery has been established, supporting multiple projects in clinical development [50]. Competitive Position - The company has successfully navigated the challenges posed by national drug procurement policies, with a significant portion of its core products already included in procurement programs [32][43]. - The upcoming unified procurement for previously selected products is expected to stabilize cash flow and enhance the company's competitive position in the generics market [42][43].

Investment Rating - The report assigns an "Outperform" rating for the company, marking its first coverage [2][7]. Core Insights - The company is a leading domestic magnetic component manufacturer, enhancing its overseas presence and actively entering the solid-state transformer market [4][5]. - The company plans to establish overseas subsidiaries in Mexico and Vietnam with an investment of up to 500 million RMB to expand its international market presence [3]. - The magnetic components market is projected to reach $27.2 billion by 2031, with a CAGR of 5.1% from 2025 to 2031, driven by demand in various sectors including new energy vehicles and data centers [4][34]. - The solid-state transformer is expected to become a key power supply solution in the AIDC era, with a potential market size of 87 billion RMB by 2030 [5][59]. Summary by Sections Company Overview - Established in 1995, the company has strengthened its magnetic component business through acquisitions and international expansion, including a subsidiary in Vietnam and plans for a factory in Mexico [4][15]. - The company has long-term partnerships with major clients such as BYD, Bosch, and Huawei, enhancing its market position [4][8]. Business Segments - The company’s revenue is primarily derived from magnetic components (83%) and switch power supplies (17%) [25]. - The magnetic components are crucial for applications in electric vehicles, energy storage, and AI servers, with expected revenue growth of 24.8% to 24.2% from 2025 to 2027 [75][76]. Financial Performance - The company reported a revenue of 4.105 billion RMB in the first three quarters of 2025, a year-on-year increase of 24.86%, with a net profit of 232 million RMB, up 52.51% [63]. - The gross margin for magnetic components improved to 12.17% in the first half of 2025, reflecting better operational management [30][70]. Market Trends - The magnetic components industry is experiencing robust growth due to increasing demand in new energy vehicles and data centers, with significant opportunities in solid-state transformers as the market evolves [34][44]. - The company is positioned to benefit from the transition to high-efficiency power supply solutions, particularly in the context of rising power demands in data centers [5][44].

证券研究报告 海大集团 (002311 CH) 国内价值属性增强，海外持续高成长 2026 年 1 月 27 日│中国内地 饲料 公司近期上调 2025-2027 年未来三年分红率由 30%至 50%，并向香港联交 所递交了海外业务分拆上市的申请文件。我们认为，当前市场对海大集团国 内业务的分红价值以及海外成长空间仍有预期差，公司 2025 年国内饲料主 业超额优势进一步放大，且单吨盈利壁垒稳固，此外，公司饲料出海持续高 增长，港股上市将加快公司海外产能布局、理顺海外管理与激励思路。重点 推荐国内长期超额优势向分红价值转化、海外盈利水平&成长性双高的稀缺 资产海大集团，维持"买入"评级。 国内主业优势稳固，自由现金流、分红率有望回升 （1）公司国内饲料主业竞争力进一步放大，我们预测，海大集团 2025 年 国内饲料外销量增长约 20%，大幅超出行业约 6%的增速，市占率加速提升； 在激烈的市场竞争下，公司饲料吨毛利长期韧性突出，以 2015 年为基期， 25H1 主要饲料上市公司饲料吨毛利下降 190 元，海大集团仅微降 6 元。我 们认为，公司 2030 年实现国内 4430 万吨饲料产销量目标的确定性不断 ...